Metabolic effects of fluoxetine in obese menopausal women.
Our objective was to assess thermogenic action of fluoxetine (FL) in obese menopausal women, evaluating the effect of FL administration on resting energy expenditure (REE) and on glucose-induced thermogenesis both after acute administration (40 mg in single dose the evening before measurements) and after a 12- week period of diet treatment plus FL (60 mg per day) or placebo. It was a double-blind, placebo-controlled design both in acute and in chronic study. The subjects were 32 obese, otherwise healthy, menopausal women. The patients were assigned randomly to three groups, one performing an acute study protocol, in which resting and glucose-induced thermogenesis was measured after FL and placebo administration, performed in randomised order. The other two groups underwent dietary plus pharmacological treatment (FL or placebo, PL). Resting and glucose-induced thermogenesis was measured at baseline and after 12 weeks of treatment. The results showed that acute FL administration caused an increase in resting energy expenditure (PL: 5.35+/-0.18 vs FL: 5.53+/-0.24 KJ/min, p<0.05). A significant decrease of REE was observed in the PL group after 12 weeks (p<0.03), while a slight, but not significant, decrease was observed in the FL group (p=NS). FL did not affect thermic response to oral glucose neither after acute nor chronic administration (p=NS for all groups studied). The conclusion was that our data give support to thermogenic actions of FL after acute administration, suggesting also that chronic FL treatment may restrain to some degree the metabolic adaptation expected during weight loss in obese subjects. At variance with what observed with other drugs, such as dexfenfluramine, an increased thermic effect of oral glucose does not seem to be involved in the thermogenetic action of FL.
Bondi
M
M
Centro di Nutrizione Clinica e Malattie del Metabolismo, Dipartimento di Medicina Interna, Università di Modena, Italy.
Menozzi
R
R
Bertolini
M
M
Venneri
M G
MG
Del Rio
G
G
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001833:Body Temperature Regulation / Q000187:drug effects*; D004311:Double-Blind Method; D004734:Energy Metabolism / Q000187:drug effects*; D005215:Fasting; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005947:Glucose / Q000008:administration & dosage; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000378:metabolism*; D010919:Placebos; D015431:Weight Loss
D018687:Antidepressive Agents, Second-Generation; D001786:Blood Glucose; D007328:Insulin; D010919:Placebos; D005473:Fluoxetine; D005947:Glucose